EJHaem · 2026
Characteristics of Clinical Response in Patients With Chronic Myeloid Leukemia With an ABL1 In-Frame Exon 4 Deletion: A Multicenter Retrospective Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaneda Yuto, Kanemura Nobuhiro, Ikoma Yoshikazu, Matsumoto Takuro, Nakamura Nobuhiko, Nakamura Hiroshi, Kasahara Senji, Fukuno Kenji, Tsukune Yutaka, Takaku Tomoiku, Shimizu Masahito
Аннотация
INTRODUCTION: In-frame Exon 4 deletion (p.L184_K274del) is a rare ABL1 splicing variant in chronic myeloid leukemia (CML), the clinical significance of which remains unclear.
METHODS: We retrospectively analyzed seven chronic-phase CML patients with this variant, identified by Sanger sequencing during routine monitoring of atypically slow molecular responses.
RESULTS: All patients achieved hematologic responses; molecular responses, although attained, were often delayed. No patient progressed to advanced phase disease during a median follow-up of 39.0 months.
CONCLUSION: Detection of this kinase-inactive variant should not, in itself, be regarded as a definitive resistance mechanism. Larger collaborative studies using quantitative methodologies are needed.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: We retrospectively analyzed seven chronic-phase CML patients with this variant, identified by Sanger sequencing during routine monitoring of atypically slow molecular responses.
RESULTS: All patients achieved hematologic responses; molecular responses, although attained, were often delayed. No patient progressed to advanced phase disease during a median follow-up of 39.0 months.
CONCLUSION: Detection of this kinase-inactive variant should not, in itself, be regarded as a definitive resistance mechanism. Larger collaborative studies using quantitative methodologies are needed.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.